PT - JOURNAL ARTICLE AU - Zouridis, Andreas AU - Zarrindej, Kianoush AU - Rencher, Joshua AU - Pappa, Christina AU - Kashif, Ammara AU - Smyth, Sarah Louise AU - Sadeghi, Negin AU - Sattar, Alisha Alisha AU - Damato, Stephen AU - Ferrari, Federico AU - Laganà, Antonio Simone AU - Abdalla, Mostafa AU - Kehoe, Sean AU - Addley, Susan AU - Majd, Hooman Soleymani TI - #1117 The prognostic characteristics and recurrence patterns of high grade endometrioid endometrial cancer: a large retrospective analysis of a tertiary center AID - 10.1136/ijgc-2023-ESGO.417 DP - 2023 Sep 01 TA - International Journal of Gynecologic Cancer PG - A203--A203 VI - 33 IP - Suppl 3 4099 - http://ijgc.bmj.com/content/33/Suppl_3/A203.1.short 4100 - http://ijgc.bmj.com/content/33/Suppl_3/A203.1.full SO - Int J Gynecol Cancer2023 Sep 01; 33 AB - Introduction/Background High grade endometrioid endometrial cancer (HGEEC) is a heterogeneous group of tumors with unclear prognostic features. The aim of the present study is to evaluate the independent risk factors for recurrence and mortality and to describe the recurrence patterns of HGEEC.Methodology Ninety-six consecutive cases of HGEEC treated with primary surgery in a single Tertiary Center were retrospectively reviewed. Clinicopathological and treatment details were recorded, and all patients were closely followed up.Results Disease-free, overall and cancer-specific survival rates were 83.8%, 77.8% and 83.6%, respectively. Cervical stromal involvement was independently related to recurrence (HR = 25.67; 95%CI 2.95–223.30; p = 0.003) and cancer-related death (HR = 15.39; 95%CI 1.29–183.43; p = 0.031) after adjusting for other pathological and treatment variables. Recurrence rate was 16%, with 60% of these cases having lung metastases and only one case with single vaginal vault recurrence. 81.81% of the recurrences presented with symptoms and not a single recurrence was diagnosed in routine follow-up clinical examination.Conclusion In conclusion, the recurrence pattern may suggest that patient-initiated follow-up (PIFU) could be considered a potential alternative to clinical-based follow-up for HGEEC survivors, especially for patients without cervical involvement and after two years from treatment. Additional caution is needed in patients with cervical stromal involvement.Disclosures Authors have nothing to disclose